GLP-1 Medications and Bone Health: What You Need to Know
A recent study published in the Journal of Clinical Endocrinology & Metabolism has shed light on the potential risks associated with GLP-1 medications, such as Ozempic and Wegovy, for older adults with Type 2 diabetes.
The study found that older adults who started GLP-1 medications had an 11% higher risk of fragility fractures compared to those taking other diabetes medications. Fragility fractures are breaks resulting from minor falls or routine activities, often linked to osteoporosis.
Understanding the Risks
Dr. Michal Kasher Meron, the lead author of the study, emphasizes the importance of paying attention to bone health in this population. Both older age and Type 2 diabetes are independent risk factors for fragility fractures, making this an area of concern.
The study followed over 46,000 adults aged 65 and older for nearly three years, revealing a modest but statistically significant increase in fracture risk for GLP-1 users.
Observational Findings
While the study shows an association between GLP-1 medications and fracture risks, it does not establish causation. Researchers were unable to determine whether the risk was driven by muscle loss or a direct effect on bone.
Additionally, separate research presented at the American Academy of Orthopaedic Surgeons' annual meeting raised concerns about osteoporosis and gout risks in GLP-1 users.
Potential Mechanisms
Experts suggest that the appetite-suppressing nature of GLP-1 medications can lead to rapid weight loss, which may reduce bone density. This is partly due to the reduced mechanical load on the skeleton.
Furthermore, rapid weight loss can increase uric acid levels, potentially explaining the higher rates of gout observed in GLP-1 users.
Expert Advice
Despite these findings, experts emphasize that GLP-1 medications should not be discouraged for appropriate use. They have proven benefits for blood sugar control, weight loss, and cardiovascular risk reduction.
However, they advise close monitoring of bone health before starting these medications, especially with the increasing prescription of more potent GLP-1 versions.
Ensuring adequate nutrition and calcium, vitamin D, and protein intake is crucial to preserving muscle and bone during weight loss.
Manufacturer's Response
Novo Nordisk, the manufacturer of GLP-1 medications, prioritizes patient safety and works closely with the FDA. They welcome independent research and emphasize the known risks and benefits reflected in the current FDA-approved labeling.
Liz Skrbkova, head of U.S. media relations for Novo Nordisk, highlights the cardiovascular, kidney, and liver benefits of semaglutide when used under medical supervision.